Review of Evolocumab for the Reduction of LDL Cholesterol and Secondary Prevention of Atherosclerotic Cardiovascular Disease

Review of Evolocumab for the Reduction of LDL Cholesterol and Secondary Prevention of Atherosclerotic Cardiovascular Disease

Elevated low-density lipoprotein cholesterol (LDL-C) is a major causal factor for atherosclerotic cardiovascular disease (ASCVD), the leading cause of mortality worldwide. Statins are the recommended first-line lipid-lowering therapy (LLT) for patients with primary hypercholesterolemia and establish...

Full description

Bibliographic Details
Main Authors: Lawrence A. Leiter, Robert A. Hegele, Vivien Brown, Jean Bergeron, Erin S. Mackinnon, G. B. John Mancini
Format: Article
Language:English
Published: IMR Press 2024-05-01
Series:Reviews in Cardiovascular Medicine
Subjects:
evolocumab
proprotein convertase subtilisin-kexin type 9 (pcsk9) inhibitor
lipid-lowering therapy
low-density lipoprotein cholesterol (ldl-c)
atherosclerotic cardiovascular disease (ascvd)
cardiovascular outcomes
Online Access:https://www.imrpress.com/journal/RCM/25/5/10.31083/j.rcm2505190

Internet

https://www.imrpress.com/journal/RCM/25/5/10.31083/j.rcm2505190

Similar Items